Investors

Recent Releases

February 12, 2026

Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 26, 2026, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year of 2025.

January 15, 2026

Emergent Announces Resolution of New York Attorney General Investigation

Emergent BioSolutions has reached an agreement with the Office of the Attorney General of the State of New York (OAG) to resolve its investigation related to legacy claims regarding the company’s approval of an executive trading plan in November 2020.

January 14, 2026

Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN® Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness

Since the U.S. prescription launch of NARCAN® Nasal Spray in 2016, the medicine has been trusted as a safe, effective way to reverse opioid overdoses, and today, new solutions like the NARCAN® carrying case aims to make accessibility paramount - ‘Trusted Then. Trusted Now’ GAITHERSBURG, Md. , Jan.